Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1/2 mutations (germline and/or somatic), to be used in combination with prednisone/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1/2-driven tumor vulnerabilities.
FDA submission anticipated based on PROpel mHSPC data
Global Expansion
2026-2027
Japan, China regulatory filings
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch performance, U.S. regulatory expansion, and competitive positioning for AKEEGA in mHSPC. Actual results may differ due to reimbursement negotiations, BRCA testing adoption rates, and competitive dynamics with PARP inhibitor combinations.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
